FDA Advisory Committee Disclosures Sought In Public Citizen Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Unredacted curricula vitae could disclose privately funded grants, pending clinical trials, and pending publications among other information.
You may also be interested in...
Advisory Committees: FDA Gets Out Of The Redaction Business
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.
Advisory Committees: US FDA Gets Out Of The Redaction Business
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.